drugset
drugset / Trial / NCT05025085

A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors

NCT05025085 ↗

Phase 1 Completed 25 enrolled Agenus Inc.
RandomizedSequentialOpen-labelTreatment

Summary

This study is a multicenter, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AGEN1777 as a single agent and when used in combination with a PD-1 inhibitor in participants with advanced, metastatic solid tumors.

Timeline

Start
2021-10-04
Primary completion
2023-07-11
Completion
2024-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject AGEN1777 Unknown — Intravenous

Indications

No indication recorded.